- Nachrichtendetail
-
02.02.2024 07:00:49 - dpa-AFX: EQS-Adhoc: Medacta Group SA: Medacta Group SA revenues up +19.5% at constant currency1 exceeding the milestone of 500Mln EUR in FY 2023 (english)
Medacta Group SA: Medacta Group SA revenues up +19.5% at constant currency1
exceeding the milestone of 500Mln EUR in FY 2023
Medacta Group SA / Key word(s): Sales Result
Medacta Group SA: Medacta Group SA revenues up +19.5% at constant currency1
exceeding the milestone of 500Mln EUR in FY 2023
02-Feb-2024 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Press Release - Ad-hoc announcement pursuant to Art. 53 LR
Medacta Group SA revenues up +19.5% at constant currency1 exceeding the
milestone of Euro 500Mln in FY 2023
* Robust supply chain key to enabling the accelerated growth;
* Strong focus maintained on Medical Education;
CASTEL SAN PIETRO, 2 February 2024 - Medacta Group SA ("Medacta", SIX:MOVE)
announces today the full year 2023 preliminary unaudited revenue.
Francesco Siccardi, CEO of Medacta, commented: "We conclude another year
with outstanding growth. Our strong commitment to innovate responsibly and
sustainably, through minimally invasive techniques and personalized
solutions remains one of the key pillars of our successful strategy. Our
comprehensive offer and ongoing investments to support continuous growth
will allow us to face the challenges that lie ahead in 2024, marking our 25th
anniversary."
In 2023 we delivered solid organic growth, with a significant gain of new
customers across all geographies and business lines. On top of the effective
commercial development, we experienced some tailwind thanks to the recovery
of the accumulated backlog mainly in USA and Australia.
Supply chain remains a key factor for our success, and in this regard, we
launched two main projects to support our future plans: the inauguration of
a new distribution center in Memphis for the US market and the expansion of
our manufacturing plants in Switzerland.
Innovation is at the core of our growth strategy and allows us to
differentiate our product offering and service portfolio. In October we
launched GMK SpheriKA, the world's first knee implant optimized for
Kinematic Alignment (KA), to improve patient satisfaction compared to more
traditional techniques. Our continued commitment to medical education,
through in-person scientific events and our M.O.R.E. Institute programs for
surgeons, has been foundational to excellent performance throughout the
entire 2023.
Revenue by geography and product line
Group performance was very positive in every market thanks to a confirmed
strong growth in EMEA, North America, and APAC. In every region the growth
was sustained by organically expanding our salesforce and customer base
together with some new product introduction.
Revenue in EMEA grew c.c. 22.6%, to Euro 242.4 million, a significant
performance driven by all the Business lines.
Revenue in North America increased 15.7% c.c. to Euro 154.0 million, a
strong performance boosted by some patient backlog recovery in the first
half of the year.
Revenue in Asia Pacific grew by 19.4% c.c. to Euro 104.2 million.
Revenue in Latin America was Euro 10.2 million with an increase of 11.9%
c.c.
Below we report the FY 2023 sales break-down by geographic area:
Hip products increased revenue by 15.5% c.c., to Euro 229.8 million, with
good performance in all geographies mainly driven by our Anterior Minimally
Invasive Surgery Approach (AMIS) and Hip revision.
Revenue from our Knee offerings grew in every market by 23.2% c.c. to Euro
198.3 million, thanks to a solid and complete product offering based on our
personalized kinematic alignment solutions (MyKA).
Our Extremities business line reported an increase in revenue of 33.8% c.c.,
to Euro 36.3 million, primarily attributable to Shoulder through the Medacta
Shoulder System and Technologies (MyShoulderand NextAR). The Sportsmed
business, which is in an early start-up phase, continued to develop its
growth plan.
Revenue from our Spine offering increased by 15.2% c.c. to Euro 46.4 million,
driven by performance recorded in EMEA and North America. Growth in APAC was
partially offset by price cuts in Japan. Good acceleration seen on NextAR
Spine utilization, recently supported by a clinical study which highlights
its efficiency in spine surgery.
Below we report the FY2023 sales break-down by product line:
These preliminary sales figures are unaudited for the period ending 31
December 2023 and are therefore subject to change. The Company will announce
its 2023 Full Year Results on 13 March 2024.
Webcast Today at 3:00 pm (CET)
Medacta Group SA will present its preliminary unaudited top-line figures
during a webcast today at 3:00 pm (CET). The call will be headed by
Francesco Siccardi (CEO) and Corrado Farsetta (CFO) and will be held in
English.
Live-Link:
https://event.choruscall.com/mediaframe/webcast.html?webcastid=IVGOqNGP
Dial-in numbers for conference call function only:
CH: +41 225954727
DE: +49 6917415713
UK: +44 1 212818003
USA: +1 718 7058794
ITA: +39 02 36213011
Contact
Medacta International SA
Giorgio Botta, Head of Investor Relations
Phone: +41 91 696 14 95
investor.relations@medacta.ch
About Medacta
Medacta is an international company specializing in the design, production,
and distribution of innovative orthopaedic products, as well as in the
development of accompanying surgical techniques. Established in 1999 in
Switzerland, Medacta is active in joint replacement, spine surgery, and
sports medicine. Medacta is committed to improving the care and well-being
of patients and maintains a strong focus on healthcare sustainability.
Medacta's innovation, forged by close collaboration with surgeon leaders
globally, began with minimally invasive surgical techniques and has evolved
into personalized solutions for every patient. Through the M.O.R.E.
Institute, Medacta supports surgeons with a comprehensive and tailored
program dedicated to the advancement of medical education. Medacta is
headquartered in Castel San Pietro, Switzerland, and operates in over 50
countries.
Disclaimer
This press release has been prepared by Medacta Group SA ('Medacta' and
together with its subsidiaries, 'we', 'us' or the 'Group'). The information
contained in the press release does not purport to be comprehensive and is
not to be taken as containing any securities advice, recommendation, offer
or invitation to subscribe for, purchase or redeem any securities regarding
Medacta.
Forward-looking information
This press release has been prepared by Medacta and includes forward-looking
information and statements concerning the outlook for its business. These
statements are based on current expectations, estimates and projections
about the factors that may affect its future performance. These
expectations, estimates and projections are generally identifiable by
statements containing words such as 'expects', 'believes', 'estimates',
'targets', 'plans', 'outlook' or similar expressions. Although Medacta
believes that its expectations reflected in any such forward-looking
statement are based upon reasonable assumptions, it can give no assurance
that those expectations will be achieved.
1 Alternative Performance Measures
This press release contains certain information that it refers to as
"constant currency" or c.c., which is a non-IFRS financial measure and
represents the total change between periods excluding the effect of changes
in foreign currency exchange rates. The Group believes that the
reconciliations of changes in constant currency provide useful supplementary
information to investors in light of fluctuations in foreign currency
exchange rates. Furthermore, the Group believes that constant currency
measures provide additional useful information on the Group's operational
performance and is consistent with how the business performance is measured
internally. Definitions of Alternative Performance Measures and
reconciliations between such measures and their IFRS counterparts may be
found on the Financial Reports available on our website at:
https://www.medacta.com/EN/financial-reports-and-presentations
Related Trademarks
Medacta Group Related Trademarks are registered at least in Switzerland. The
products and services listed below may not be all-inclusive, and other
Medacta products and services not listed below may be covered by one or more
trademarks. The below products and services may be covered by additional
trademarks not listed below. Note that Swiss trademarks may have foreign
counterparts.
MyShoulder®, NextAR(TM), GMK® Sphere, MyKA(TM), GMK® SpheriKA, AMIS®.
---------------------------------------------------------------------------
End of Inside Information
---------------------------------------------------------------------------
End of Announcement EQS News Service
---------------------------------------------------------------------------
1828325 02-Feb-2024 CET/CEST
exceeding the milestone of 500Mln EUR in FY 2023
Medacta Group SA / Key word(s): Sales Result
Medacta Group SA: Medacta Group SA revenues up +19.5% at constant currency1
exceeding the milestone of 500Mln EUR in FY 2023
02-Feb-2024 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Press Release - Ad-hoc announcement pursuant to Art. 53 LR
Medacta Group SA revenues up +19.5% at constant currency1 exceeding the
milestone of Euro 500Mln in FY 2023
* FY 2023 revenue increased to Euro 510.8 million, or 19.5% c.c.1 (16.8%
reported) from FY 2022;
* Strongest growth occurred in EMEA with very good performance in APAC and
North America;
* Positive contributions from every business line with excellent results
in Knee and Shoulder;
* Robust supply chain key to enabling the accelerated growth;
* Strong focus maintained on Medical Education;
* 193 new jobs created, including salesforce expansion surpassing 1'700
employees at Group level.
CASTEL SAN PIETRO, 2 February 2024 - Medacta Group SA ("Medacta", SIX:MOVE)
announces today the full year 2023 preliminary unaudited revenue.
Francesco Siccardi, CEO of Medacta, commented: "We conclude another year
with outstanding growth. Our strong commitment to innovate responsibly and
sustainably, through minimally invasive techniques and personalized
solutions remains one of the key pillars of our successful strategy. Our
comprehensive offer and ongoing investments to support continuous growth
will allow us to face the challenges that lie ahead in 2024, marking our 25th
anniversary."
In 2023 we delivered solid organic growth, with a significant gain of new
customers across all geographies and business lines. On top of the effective
commercial development, we experienced some tailwind thanks to the recovery
of the accumulated backlog mainly in USA and Australia.
Supply chain remains a key factor for our success, and in this regard, we
launched two main projects to support our future plans: the inauguration of
a new distribution center in Memphis for the US market and the expansion of
our manufacturing plants in Switzerland.
Innovation is at the core of our growth strategy and allows us to
differentiate our product offering and service portfolio. In October we
launched GMK SpheriKA, the world's first knee implant optimized for
Kinematic Alignment (KA), to improve patient satisfaction compared to more
traditional techniques. Our continued commitment to medical education,
through in-person scientific events and our M.O.R.E. Institute programs for
surgeons, has been foundational to excellent performance throughout the
entire 2023.
Revenue by geography and product line
Group performance was very positive in every market thanks to a confirmed
strong growth in EMEA, North America, and APAC. In every region the growth
was sustained by organically expanding our salesforce and customer base
together with some new product introduction.
Revenue in EMEA grew c.c. 22.6%, to Euro 242.4 million, a significant
performance driven by all the Business lines.
Revenue in North America increased 15.7% c.c. to Euro 154.0 million, a
strong performance boosted by some patient backlog recovery in the first
half of the year.
Revenue in Asia Pacific grew by 19.4% c.c. to Euro 104.2 million.
Revenue in Latin America was Euro 10.2 million with an increase of 11.9%
c.c.
Below we report the FY 2023 sales break-down by geographic area:
(Million Euro) FY FY Re- Con-
2023 2022 po- sta-
rt- nt
ed Cur-
Gr- ren-
ow- cy
th Gro-
wth
EMEA* 242.4 196.7 23- 22.-
.3- 6%
%
North America 154.0 136.8 12- 15.-
.6- 7%
%
Asia Pacific 104.2 94.4 10- 19.-
.4- 4%
%
Latin America* 10.2 9.3 9.- 11.-
0% 9%
TOTAL 510.8 437.1 16- 19.-
.8- 5%
%
* EMEA and Latin America (LATAM): In 2023 we
reorganized the key geographic areas introducing
EMEA and LATAM regions, reclassifying Rest of the
World (RoW) region. EMEA includes revenue from the
former Europe region and certain countries
originally included in RoW region. LATAM includes
revenue from countries located in Latin America
which were previously included in RoW. 2022
figures have been restated accordingly.
Hip products increased revenue by 15.5% c.c., to Euro 229.8 million, with
good performance in all geographies mainly driven by our Anterior Minimally
Invasive Surgery Approach (AMIS) and Hip revision.
Revenue from our Knee offerings grew in every market by 23.2% c.c. to Euro
198.3 million, thanks to a solid and complete product offering based on our
personalized kinematic alignment solutions (MyKA).
Our Extremities business line reported an increase in revenue of 33.8% c.c.,
to Euro 36.3 million, primarily attributable to Shoulder through the Medacta
Shoulder System and Technologies (MyShoulderand NextAR). The Sportsmed
business, which is in an early start-up phase, continued to develop its
growth plan.
Revenue from our Spine offering increased by 15.2% c.c. to Euro 46.4 million,
driven by performance recorded in EMEA and North America. Growth in APAC was
partially offset by price cuts in Japan. Good acceleration seen on NextAR
Spine utilization, recently supported by a clinical study which highlights
its efficiency in spine surgery.
Below we report the FY2023 sales break-down by product line:
(Million Euro) FY FY Reported Constant
2023 2022 Growth Currency
Growth
Hip 229.8 203.6 12.9% 15.5%
Knee 198.3 164.5 20.6% 23.2%
Extremities* 36.3 27.5 31.9% 33.8%
Spine 46.4 41.5 11.7% 15.2%
TOTAL 510.8 437.1 16.8% 19.5%
* Extremities include Shoulder
and Sportsmed revenues
These preliminary sales figures are unaudited for the period ending 31
December 2023 and are therefore subject to change. The Company will announce
its 2023 Full Year Results on 13 March 2024.
Webcast Today at 3:00 pm (CET)
Medacta Group SA will present its preliminary unaudited top-line figures
during a webcast today at 3:00 pm (CET). The call will be headed by
Francesco Siccardi (CEO) and Corrado Farsetta (CFO) and will be held in
English.
Live-Link:
https://event.choruscall.com/mediaframe/webcast.html?webcastid=IVGOqNGP
Dial-in numbers for conference call function only:
CH: +41 225954727
DE: +49 6917415713
UK: +44 1 212818003
USA: +1 718 7058794
ITA: +39 02 36213011
Contact
Medacta International SA
Giorgio Botta, Head of Investor Relations
Phone: +41 91 696 14 95
investor.relations@medacta.ch
About Medacta
Medacta is an international company specializing in the design, production,
and distribution of innovative orthopaedic products, as well as in the
development of accompanying surgical techniques. Established in 1999 in
Switzerland, Medacta is active in joint replacement, spine surgery, and
sports medicine. Medacta is committed to improving the care and well-being
of patients and maintains a strong focus on healthcare sustainability.
Medacta's innovation, forged by close collaboration with surgeon leaders
globally, began with minimally invasive surgical techniques and has evolved
into personalized solutions for every patient. Through the M.O.R.E.
Institute, Medacta supports surgeons with a comprehensive and tailored
program dedicated to the advancement of medical education. Medacta is
headquartered in Castel San Pietro, Switzerland, and operates in over 50
countries.
Disclaimer
This press release has been prepared by Medacta Group SA ('Medacta' and
together with its subsidiaries, 'we', 'us' or the 'Group'). The information
contained in the press release does not purport to be comprehensive and is
not to be taken as containing any securities advice, recommendation, offer
or invitation to subscribe for, purchase or redeem any securities regarding
Medacta.
Forward-looking information
This press release has been prepared by Medacta and includes forward-looking
information and statements concerning the outlook for its business. These
statements are based on current expectations, estimates and projections
about the factors that may affect its future performance. These
expectations, estimates and projections are generally identifiable by
statements containing words such as 'expects', 'believes', 'estimates',
'targets', 'plans', 'outlook' or similar expressions. Although Medacta
believes that its expectations reflected in any such forward-looking
statement are based upon reasonable assumptions, it can give no assurance
that those expectations will be achieved.
1 Alternative Performance Measures
This press release contains certain information that it refers to as
"constant currency" or c.c., which is a non-IFRS financial measure and
represents the total change between periods excluding the effect of changes
in foreign currency exchange rates. The Group believes that the
reconciliations of changes in constant currency provide useful supplementary
information to investors in light of fluctuations in foreign currency
exchange rates. Furthermore, the Group believes that constant currency
measures provide additional useful information on the Group's operational
performance and is consistent with how the business performance is measured
internally. Definitions of Alternative Performance Measures and
reconciliations between such measures and their IFRS counterparts may be
found on the Financial Reports available on our website at:
https://www.medacta.com/EN/financial-reports-and-presentations
Related Trademarks
Medacta Group Related Trademarks are registered at least in Switzerland. The
products and services listed below may not be all-inclusive, and other
Medacta products and services not listed below may be covered by one or more
trademarks. The below products and services may be covered by additional
trademarks not listed below. Note that Swiss trademarks may have foreign
counterparts.
MyShoulder®, NextAR(TM), GMK® Sphere, MyKA(TM), GMK® SpheriKA, AMIS®.
---------------------------------------------------------------------------
End of Inside Information
---------------------------------------------------------------------------
Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: info@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 1828325
End of Announcement EQS News Service
---------------------------------------------------------------------------
1828325 02-Feb-2024 CET/CEST
